Interventional device manufacturer Boston Scientific said that enrollment has begun in the Syntax clinical trial, which will compare the performance of drug-eluting stents with cardiac surgery in patients with coronary artery disease in all three coronary arteries, in the left main coronary artery, or both.
The randomized, controlled clinical trial is designed to compare 12-month outcomes of percutaneous coronary intervention using Boston Scientific's Taxus Express2 paclitaxel-eluting coronary stent system with coronary artery bypass graft treatment. Syntax is a multicenter, prospective trial that will involve more than 4,200 patients at up to 90 sites in Europe and the U.S., according to the Natick, MA-based firm.
By AuntMinnie.com staff writers
April 12, 2005
Related Reading
Boston Scientific adds CE Mark
Boston Scientific gets FDA OK for Taxus in MRI, April 5, 2005
Boston Scientific loses stent verdict, March 25, 2005
Boston Scientific continues robust growth, February 1, 2005
Court issues judgment in stent patent dispute, January 6, 2005
Copyright © 2005 AuntMinnie.com
